Přejít k obsahu
Merck
  • Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide.

Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide.

Molecular medicine (Cambridge, Mass.) (2012-09-25)
Maarten Swartjes, René A G Mooren, Amanda R Waxman, Caroline Arout, Koen van de Wetering, Jan den Hartigh, Jos H Beijnen, Benjamin Kest, Albert Dahan
ANOTACE

Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain perception that may manifest during opioid treatment. For morphine, the metabolite morphine-3-glucuronide (M3G) is commonly believed to underlie this phenomenon. Here, in three separate studies, we empirically assess the role of M3G in morphine-induced hyperalgesia. In the first study, CD-1 mice injected with morphine (15 mg/kg subcutaneously) after pretreatment with the opioid receptor antagonist naltrexone (NTX) (15 mg/kg) showed tail withdrawal latency reductions indicative of hyperalgesia (2.5 ± 0.1 s at t = 30 min, P < 0.001 versus baseline). In these mice, the morphine/M3G concentration ratios versus effect showed a negative correlation (r(p) = -0.65, P < 0.001), indicating that higher morphine relative to M3G concentrations are associated with increased OIH. In the second study, similar hyperalgesic responses were observed in mice lacking the multidrug resistance protein 3 (MRP3) transporter protein (Mrp3(-/-) mice) in the liver and their wild-type controls (FVB mice; latency reductions: 3.1 ± 0.2 s at t = 30 min, P < 0.001 versus within-strain baseline). In the final study, the pharmacokinetics of morphine and M3G were measured in Mrp3(-/-) and FVB mice. Mrp3(-/-) mice displayed a significantly reduced capacity to export M3G into the systemic circulation, with plasma M3G concentrations just 7% of those observed in FVB controls. The data confirm previous literature that morphine causes hyperalgesia in the absence of opioid receptor activation but also indicate that this hyperalgesia may occur without a significant contribution of hepatic M3G. The relevance of these data to humans has yet to be demonstrated.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Supelco
Morphine-3-β-D-glucuronide solution, 1 mg/mL in methanol with 0.05% NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Morphine-3-β-D-glucuronide solution, 100 μg/mL in methanol: water ( 50:50(v/v)), ampule of 1 mL, certified reference material, Cerilliant®